299
Views
16
CrossRef citations to date
0
Altmetric
Review

Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data

ORCID Icon, , ORCID Icon, , , ORCID Icon, , , , & show all
Pages 4697-4711 | Published online: 29 Dec 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Ilias Karaiskos, Irene Galani, Vassiliki Papoutsaki, Lamprini Galani & Helen Giamarellou. (2022) Carbapenemase producing Klebsiella pneumoniae: implication on future therapeutic strategies. Expert Review of Anti-infective Therapy 20:1, pages 53-69.
Read now
Milo Gatti, Bruno Viaggi, Gian Maria Rossolini, Federico Pea & Pierluigi Viale. (2021) An Evidence-Based Multidisciplinary Approach Focused at Creating Algorithms for Targeted Therapy of BSIs, cUTIs, and cIAIs Caused by Enterobacterales in Critically Ill Adult Patients. Infection and Drug Resistance 14, pages 2461-2498.
Read now

Articles from other publishers (14)

Carolin Prinz, Frank Streit, Christian Schumann, Anna Dudakova, Christian Lanckohr, Julie Schanz, Matthias Bohn, Uwe Groß, Konrad Meissner, Onnen Moerer & Lars-Olav Harnisch. (2023) Feasibility of Continuous Infusion of Cefiderocol in Conjunction with the Establishment of Therapeutic Drug Monitoring in Patients with Extensively Drug-Resistant Gram-Negative Bacteria. Clinical Drug Investigation 43:4, pages 307-314.
Crossref
Xiuyun Li, Jing Zhao, Bin Zhang, Xuexia Duan, Jin Jiao, Weiwei Wu, Yuxia Zhou & Hefeng Wang. (2022) Drug development concerning metallo-β-lactamases in gram-negative bacteria. Frontiers in Microbiology 13.
Crossref
Helen Giamarellou & Ilias Karaiskos. (2022) Current and Potential Therapeutic Options for Infections Caused by Difficult-to-Treat and Pandrug Resistant Gram-Negative Bacteria in Critically Ill Patients. Antibiotics 11:8, pages 1009.
Crossref
Angela Raffaella Losito, Francesca Raffaelli, Paola Del Giacomo & Mario Tumbarello. (2022) New Drugs for the Treatment of Pseudomonas aeruginosa Infections with Limited Treatment Options: A Narrative Review. Antibiotics 11:5, pages 579.
Crossref
Emilio Bouza & Almudena Burillo. (2022) Current international and national guidelines for managing skin and soft tissue infections. Current Opinion in Infectious Diseases 35:2, pages 61-71.
Crossref
Matteo Bassetti, Alessandra Mularoni, Daniele Roberto Giacobbe, Nadia Castaldo & Antonio Vena. (2022) New Antibiotics for Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia. Seminars in Respiratory and Critical Care Medicine 43:02, pages 280-294.
Crossref
C. Mullié, D. Lemonnier, C.C. Adjidé, J. Maizel, G. Mismacque, A. Cappe, T. Carles, M. Pierson-Marchandise & Y. Zerbib. (2022) Nosocomial outbreak of monoclonal VIM carbapenemase-producing Enterobacter cloacae complex in an intensive care unit during the COVID-19 pandemic: an integrated approach. Journal of Hospital Infection 120, pages 48-56.
Crossref
Hongmei Wang & Brittany N. Palasik. (2022) Combating antimicrobial resistance with cefiderocol for complicated infections involving the urinary tract. Therapeutic Advances in Urology 14, pages 175628722110655.
Crossref
Joanna Krajewska & Agnieszka Ewa Laudy. (2021) The European Medicines Agency Approved the New Antibacterial Drugs – Response to the 2017 Who Report on the Global Problem of Multi-Drug Resistance. Postępy Mikrobiologii - Advancements of Microbiology 60:4, pages 249-264.
Crossref
Jie Qin, Yishu Zhao, Aifang Wang, Xiaohui Chi, Peipei Wen, Shuang Li, Lingjiao Wu, Sheng Bi & Hao Xu. (2021) Comparative genomic characterization of multidrug-resistant Citrobacter spp. strains in Fennec fox imported to China. Gut Pathogens 13:1.
Crossref
Matteo Bassetti, Chiara Russo, Antonio Vena & Daniele Roberto Giacobbe. (2021) New antibiotics for the treatment of nonfermenting Gram-negative bacteria. Current Opinion in Infectious Diseases 34:6, pages 701-709.
Crossref
Luca Borghesi, Valentina Viaggi, Marco Franzetti, Matteo Montoli, Carola Mauri, Giovanni Moioli, Mauro Roberto Benvenuti, Stefania Piconi & Francesco Luzzaro. (2021) Successful prolonged cefiderocol treatment of a chronic left pleural empyema caused by Pseudomonas aeruginosa in a patient affected by COVID-19: a case report. Journal of Global Antimicrobial Resistance 27, pages 157-159.
Crossref
Marianna Meschiari, Sara Volpi, Matteo Faltoni, Giovanni Dolci, Gabriella Orlando, Erica Franceschini, Marianna Menozzi, Mario Sarti, Giovanni Del Fabro, Benedetta Fumarola, Francesco Guarneri, Paola Lanza, Silvia Lorenzotti, Barbara Saccani, Liana Signorini, Evelyn Van Hauwermeiren, Milo Gatti, Federico Pea, Francesco Castelli & Cristina Mussini. (2021) Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections . JAC-Antimicrobial Resistance 3:4.
Crossref
Nelson G.M. Gomes, Áurea Madureira-Carvalho, Diana Dias-da-Silva, Patrícia Valentão & Paula B. Andrade. (2021) Biosynthetic versatility of marine-derived fungi on the delivery of novel antibacterial agents against priority pathogens. Biomedicine & Pharmacotherapy 140, pages 111756.
Crossref